# Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

> **NCT03289910** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Atypical Chronic Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Essential Thrombocythemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelofibrosis
- Polycythemia Vera
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Topotecan
- **DRUG:** Topotecan Hydrochloride
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT03289910
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-24
- **Primary completion:** 2023-05-31
- **Final completion:** 2026-12-18
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289910, "Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03289910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*